|
Daily Medical Update
Influenza
Thursday, August 20, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
The American journal of cardiology (2026) - Meta-Analysis
Key Findings
- Influenza vaccination was associated with lower all-cause mortality (HR 0.72; 95% CI 0.63–0.82) and cardiovascular mortality (HR 0.77; 95% CI 0.67–0.89) in patients with ischemic heart disease or heart failure.
- Vaccinated patients had lower myocardial infarction risk (HR 0.81; 95% CI 0.78–0.83), while reductions in stroke and major adverse cardiovascular events were not statistically significant.
📋 Practice Implication: For patients with ischemic heart disease or heart failure, annual influenza vaccination should be treated as a cardiovascular secondary-prevention measure as well as infection prevention.
|
JAMA network open (2025) - Meta-Analysis
Key Findings
- Among influenza vaccine-naive children younger than 3 years, a second inactivated-vaccine dose was associated with a 28-percentage-point absolute increase in vaccine effectiveness (95% CI, 4.7–51).
- Across children younger than 9 years, the pooled absolute increase was 15 percentage points (95% CI, −2.8 to 33), which was not statistically significant; estimates for a second live-attenuated dose were insufficient.
📋 Practice Implication: The clearest incremental benefit is in vaccine-naive children under 3 years, so clinicians should prioritize completing the two-dose first-season series in this youngest group while recognizing less certain benefit through age 8.
|
JAMA network open (2026) - Meta-Analysis
Key Findings
- Compared with standard-dose vaccine, high-dose vaccine reduced influenza hospitalizations by 38.5% (95% CI, 26.5%–48.5%) and laboratory-confirmed influenza hospitalizations by 31.2% (19.3%–41.4%) in older adults.
- High-dose vaccine also reduced all-cause hospitalizations by 3.3% (1.8%–4.8%), but all-cause mortality did not differ significantly (relative vaccine effectiveness 0.9%; 95% CI, −2.1% to 3.8%).
📋 Practice Implication: For adults 65 years and older, high-dose vaccine offers the strongest evidence for reducing hospitalization, but expectations should not include a demonstrated all-cause mortality advantage.
|
International journal of chronic obstructive pulmonary disease (2026) - Meta-Analysis
Key Findings
- In COPD patients, pooled seroconversion was 68.6% for A/H1N1 and 65.8% for A/H3N2 in the intradermal subgroup; subcutaneous A/H3N2 seroprotection reached 96.0% in one study.
- Local erythema (31.5%) and swelling (28.7%) were more frequent with intradermal vaccination, while systemic fever occurred in fewer than 5% of participants.
📋 Practice Implication: Influenza vaccination remains immunogenic and generally tolerable in COPD; route-specific local reactions and the laboratory-to-real-world effectiveness gap should be part of patient counseling.
|
Rheumatology (Oxford, England) (2026) - Meta-Analysis
Key Findings
- Pooled influenza vaccination coverage was 50% in rheumatoid arthritis, 42% in systemic lupus erythematosus, 43% in spondyloarthritis, and 53% in psoriatic arthritis.
- Coverage remained below 55% across all four disease groups; lack of awareness and not being offered vaccination were the leading reported barriers.
📋 Practice Implication: Rheumatology visits are an actionable point for vaccine assessment and clinician recommendation, particularly for systemic lupus erythematosus and spondyloarthritis where pooled coverage was lowest.
|
|
💡
Summary
Recent influenza evidence supports vaccination as cardiovascular secondary prevention, reinforces a two-dose first-season strategy for the youngest vaccine-naive children, and favors high-dose vaccine for reducing hospitalization in adults aged 65 years and older. Additional reviews support vaccination in COPD while identifying route-specific local reactions and show persistent coverage gaps in rheumatic diseases, especially where vaccination is not proactively offered.
|
|